Nebivolol Sandoz (Nebivolol)

• Nebivolol is used in the management of cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.
• Hypertension: Reduces systolic and diastolic blood pressure in adults with essential hypertension.
• Heart failure (NYHA class II): Improves left ventricular ejection fraction and reduces symptoms in patients with mild to moderate heart failure.
• Left ventricular systolic dysfunction: Enhances cardiac output and may delay disease progression in patients with reduced ejection fraction.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric‑oxide synthase, leading to increased nitric‑oxide release and vasodilation of peripheral vessels. This dual action—β1‑blockade combined with nitric‑oxide mediated vasodilation—contributes to its antihypertensive effect while preserving vascular compliance.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild to moderate headache reported.
• Dizziness: transient light‑headedness, especially after dose initiation.
• Fatigue: general tiredness or reduced energy.
• Nausea: occasional stomach upset.
• Nasal congestion: mild nasal stuffiness.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Severe bradycardia: markedly reduced heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure leading to fainting.
• Heart block: atrioventricular conduction disturbances.
• Bronchospasm: respiratory difficulty in susceptible individuals.
• Allergic reactions: rash, pruritus, or anaphylaxis.

• When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.
• Blood pressure monitoring: Regularly assess blood pressure to avoid excessive hypotension.
• Cardiac function assessment: Evaluate heart rate and ECG, especially in patients with conduction disorders.
• Asthma or COPD caution: Use with care in patients with reactive airway disease due to potential bronchoconstriction.
• Abrupt discontinuation: Do not stop therapy suddenly; taper dose to prevent rebound hypertension.
• Renal impairment adjustment: Dose may need modification in patients with severe renal dysfunction.
• Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Nebivolol can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Other β‑blockers: Combined use may cause excessive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): May increase nebivolol plasma levels and cardiac depression.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): Can raise nebivolol concentrations, enhancing adverse effects.
• Non‑selective β‑blockers: Additive β‑blocking effects leading to severe cardiovascular depression.
• Antihypertensive combinations: Concurrent use with multiple agents may cause profound hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: May potentiate hypotensive effect; monitor electrolytes and blood pressure.
• ACE inhibitors/ARBs: Combined therapy may increase risk of symptomatic hypotension.
• NSAIDs: Can blunt antihypertensive response; observe blood pressure control.
• Antidiabetic drugs: Nebivolol may mask hypoglycemia symptoms; check glucose levels.
• Digoxin: Possible increase in serum digoxin concentrations; monitor for toxicity.